Pancreatic Cancer Research

ResearcherKyorin UniversityActive in the last 2 years

Naohiro Okano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4098-5217; OpenAlex author ID A5074130054. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
139
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 4 papers · 2023: 5 papers · 2024: 4 papers · 2025: 6 papers · 2026: 2 papers

Papers 30

  1. Prognostic impact of imaging tumor regression adjacent to major arteries after preoperative chemotherapy in surgical patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.suronc.2026.102574↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  4. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  5. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  6. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  7. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  8. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  9. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  10. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  11. Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-65900-w↗
  12. A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy. First author DOI 10.21873/anticanres.16919↗
  13. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  14. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  15. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  16. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.9504-22↗
  17. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  18. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  19. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  20. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  21. Trends in the surgical treatment for pancreatic cancer in the last 30 years. First author DOI 10.5582/bst.2022.01250↗
  22. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00489-7↗
  23. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  24. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  25. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  26. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
  27. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. Co-author DOI 10.1007/s10637-018-0589-6↗
  28. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  29. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refrac… First author DOI 10.1007/s00280-014-2665-8↗
  30. [Chemoradiotherapy for Locally Advanced Pancreatic Cancer]. Co-author PMID 26489544↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Furuse · 18 shared papers, 2015–2025 · strength 2.53
  2. Makoto Ueno · 15 shared papers, 2020–2026 · strength 2.19
  3. Masato Ozaka · 14 shared papers, 2018–2026 · strength 1.89
  4. Masafumi Ikeda · 13 shared papers, 2020–2025 · strength 1.86
  5. Nobumasa Mizuno · 12 shared papers, 2018–2026 · strength 1.38
  6. Satoshi Kobayashi · 11 shared papers, 2018–2025 · strength 1.34
  7. Chigusa Morizane · 9 shared papers, 2020–2025 · strength 1.33
  8. Hiroshi Imaoka · 7 shared papers, 2022–2025 · strength 1.06
  9. Akiko Todaka · 9 shared papers, 2018–2025 · strength 1.00
  10. Fumio Nagashima · 7 shared papers, 2015–2024 · strength 0.98
  11. Yasuyuki Kawamoto · 6 shared papers, 2022–2025 · strength 0.90
  12. Kumiko Umemoto · 6 shared papers, 2022–2025 · strength 0.90
  13. Takeshi Terashima · 5 shared papers, 2023–2025 · strength 0.85
  14. Kunihiro Tsuji · 6 shared papers, 2020–2025 · strength 0.80
  15. Akihiro Ohba · 5 shared papers, 2022–2025 · strength 0.79
  16. Kentaro Sudo · 7 shared papers, 2018–2024 · strength 0.78
  17. Yoshihiro Sakamoto · 4 shared papers, 2022–2026 · strength 0.78
  18. Takuji Okusaka · 6 shared papers, 2020–2025 · strength 0.76
  19. Keiko Kamei · 6 shared papers, 2018–2026 · strength 0.75
  20. Noritoshi Kobayashi · 6 shared papers, 2018–2025 · strength 0.70
  21. Akinori Asagi · 5 shared papers, 2020–2025 · strength 0.67
  22. Hiroaki Nagano · 4 shared papers, 2022–2025 · strength 0.63
  23. Junji Shibahara · 3 shared papers, 2023–2026 · strength 0.62
  24. Ryota Matsuki · 3 shared papers, 2022–2026 · strength 0.60
  25. Hiroshi Ishii · 5 shared papers, 2021–2023 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.